Cimetidine Decreases Theophylline Clearance

  1. MARK A. CAMPBELL, B.S., R.Ph.;
  2. JOHN R. PLACHETKA, Pharm.D.;
  3. J. EDWARD JACKSON, M.D.;
  4. JAMES F. MOON, M.D.; and
  5. PAUL R. FINLEY, M.D.
  1. Colleges of Pharmacy and Medicine, University of Arizona, Arizona Health Sciences Center;
    Tucson, Arizona

    Excerpt

    Cimetidine, an H-2 receptor antagonist, was introduced in the United States in 1977 for the treatment of duodenal ulcers. Since its introduction, approximately 11 million patients worldwide have been treated with Cimetidine (1). In 1980, Cimetidine was the 15th most commonly prescribed drug in the United States (2). Recently, numerous drug interactions involving Cimetidine have been reported; it has been shown to decrease the clearance of antipyrine, diazepam, and warfarin in humans (3, 4), as well as prolong hexobarbital sleep time and inhibit aminopyrine and caffeine demethylation in rats (5, 6). Recently, prophylactic Cimetidine has been recommended for ulcer patients

    This 100-word excerpt has been provided in the absence of an abstract.

    Article and Author Information

    • ▸Requests for reprints should be addressed to John R. Plachetka, Pharm.D.; Department of Pharmacy Practice, College of Pharmacy, University of Arizona; Tucson, AZ 85721.

    « Previous | Next Article »Table of Contents